INDO PAC J OCEAN LIFE
Volume 9, Number 1, June 2025
Pages: 46-63

P-ISSN: 2775-1961
E-ISSN: 2775-1953
DOI: 10.13057/oceanlife/o090105

Review: Bioactive compounds and therapeutic potentials of coral reef organisms

RAHMA NUR SYAMSI[1], SYARIFAH HASNA ROSYIDA[1], TALITHA NASWA ALLYSA[1], WHENY HANIFAH[1], RINOA SALSABILA IZDIHAR[1], DARLINA MD. NAIM[2], AHMAD DWI SETYAWAN[1,3,♥]

[1]Department of Environmental Science, Faculty of Mathematics and Natural Sciences, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java, Indonesia. Tel.: +62-271-669376, Fax.: +62-271-663375, ♥email: volatileoils@gmail.com
[2]School of Biological Sciences, Universiti Sains Malaysia. 11800 Penang, Malaysia
[3]Biodiversity Research Group, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java, Indonesia

Manuscript received: 17 July 2024. Revision accepted: 1 June 2025.

Abstract. *Syamsi RN, Rosyida SH, Allysa TN, Hanifah W, Izdihar RS, Naim DM, Setyawan AD. 2025. Review: Bioactive compounds and therapeutic potentials of coral reef organisms. Indo Pac J Ocean Life 9: 46-63.* Coral reef ecosystems harbor an extraordinary diversity of marine organisms that are increasingly recognized as rich sources of bioactive compounds. This review examines the biodiversity, chemical composition, and pharmacological activities of coral reef organisms, with a particular focus on soft corals, macroalgae, sponges, and their associated microorganisms. Key classes of compounds—including terpenoids, alkaloids, steroids, and sulfated polysaccharides—have demonstrated potent antibacterial, antiviral, anti-inflammatory, anticancer, and immunomodulatory properties in both in vitro and in vivo studies. Beyond laboratory findings, this study highlights the ethnopharmacological significance of coral-derived organisms in traditional healing systems across Southeast Asian coastal communities. It also explores the continuity and erosion of these practices, and discusses their potential integration into modern complementary medicine frameworks. The final sections address critical challenges in coral-based drug discovery, such as taxonomic underrepresentation, unsustainable harvesting, and regulatory constraints. At the same time, the review identifies emerging opportunities facilitated by omics technologies, synthetic biology, and interdisciplinary collaboration. By synthesizing biomedical and cultural perspectives, this review underscores the immense therapeutic potential of coral reef biodiversity and calls for integrated conservation and research strategies that ensure both ecological integrity and equitable innovation.

Keywords: Complementary medicine, drug discovery, ethnopharmacology, pharmacological activity, traditional medicine

INTRODUCTION

Coral reef ecosystems represent one of the most biologically diverse environments on the planet, harboring a wide array of marine organisms with significant ecological, economic, and biomedical relevance. Among these organisms, corals and their associated biota including sponges, tunicates, algae, echinoderms, and mollusks have emerged as prolific producers of structurally unique bioactive compounds. These compounds exhibit diverse pharmacological activities, such as anticancer, antimicrobial, antiviral, anti-inflammatory, antioxidant, neuroprotective, and antidiabetic effects, thereby attracting increasing attention in the field of drug discovery and natural product research (Mayer et al. 2013; Chen et al. 2016; Blunt et al. 2018).

The harsh and competitive environment of coral reefs has driven the evolution of sophisticated chemical defense mechanisms. These mechanisms result in the production of secondary metabolites with high potency and novel molecular scaffolds that differ significantly from terrestrial analogs. Marine organisms—particularly soft corals, gorgonians, sponges, and reef-associated macroalgae—often generate compounds with greater lipophilicity, halogenation, and stereochemical complexity, enabling interaction with previously "undruggable" molecular targets (Ermolenko et al. 2020). Such characteristics make coral reef-derived metabolites promising candidates for pharmaceutical development, particularly in the context of multidrug resistance, emerging infectious diseases, and chronic inflammatory and metabolic disorders.

Recent years have witnessed a surge in studies exploring the chemical constituents and therapeutic potentials of reef organisms, bolstered by advances in metabolomics, dereplication strategies, and synthetic biology. Innovative technologies such as genome mining, microbial fermentation, and nanocarrier-based delivery systems have opened new avenues for isolating, producing, and formulating marine bioactives (Cooper et al. 2014; Karthikeyan et al. 2022). Moreover, omics-based approaches, including transcriptomics and metagenomics, have revealed the biosynthetic gene clusters responsible for many potent metabolites—some of which originate not from the macroorganisms themselves but from their symbiotic microbial consortia.

Despite these advances, the vast majority of coral reef biodiversity remains chemically uncharacterized, especially in the tropical Indo-Pacific, home to the Coral Triangle. This region, which includes Indonesia, the Philippines, and Papua New Guinea, is recognized as the global epicenter of marine biodiversity, hosting more than 500 species of reef-building corals and a complex web of symbiotic life forms (Putnam et al. 2017; Asaad et al. 2020). Indonesia alone

harbors dozens of endemic soft coral genera such as *Sarcophyton*, *Lobophytum*, and *Sinularia*, many of which have already demonstrated pharmacologically significant activities in preliminary assays but remain underexplored in clinical contexts (Figure 1).

The urgency to study these organisms is further heightened by escalating threats to coral reef ecosystems. Anthropogenic pressures such as overfishing, eutrophication, habitat destruction, and unsustainable bioprospecting practices are rapidly degrading reef habitats, while climate change-induced stressors—including ocean acidification and thermal bleaching—pose existential risks. These pressures not only endanger the ecosystems themselves but also jeopardize the discovery of novel marine-based therapeutics (Fudjaja et al. 2020). Additionally, ethical and legal considerations—especially those outlined in the Convention on Biological Diversity and the Nagoya Protocol—emphasize the need for equitable benefit-sharing and the inclusion of local and indigenous knowledge holders in bioprospecting initiatives.

Coral reef organisms also hold an important place in the traditional medicine systems of many coastal communities across Southeast Asia. Ethnomedicinal knowledge, though often overlooked in mainstream pharmacology, provides valuable clues for identifying bioactive species and understanding the cultural significance of marine-derived therapies. In many cases, traditional uses of soft coral or sea cucumber extracts for inflammation, wound healing, or energy restoration have been substantiated by modern pharmacological studies (Pangestuti and Arifin 2017; Fristiohady et al. 2019). As such, integrating ethnopharmacology with modern drug discovery not only enhances efficiency but also fosters biocultural conservation and respect for local health traditions.

Given this background, this review aims to synthesize recent advances in the identification and pharmacological characterization of bioactive compounds derived from coral reef organisms. The review focuses on key chemical classes—including terpenoids, steroids, alkaloids, flavonoids, saponins, and prostaglandin-like compounds—and their respective therapeutic targets and structure-activity relationships. Furthermore, it highlights case studies from tropical Indo-Pacific regions, addresses the cultural and ethnopharmacological relevance of reef organisms, outlines regulatory and ethical considerations in marine bioprospecting, and discusses emerging technologies and strategies for sustainable utilization. By bridging biochemical, ecological, and socio-cultural perspectives, this review underscores the immense promise and urgent need for integrated approaches in coral reef-based drug discovery.

BIODIVERSITY AND CHEMICAL COMPOSITION OF CORAL REEFS

Overview of coral diversity

Coral reefs are composed of a wide variety of organisms, including hard corals, soft corals, sponges, algae, and other invertebrates that together form highly diverse and productive marine ecosystems (Putnam et al. 2017; Bell et al. 2022). Hard corals, also known as hermatypic corals, are responsible for building the calcium carbonate framework that defines reef structure. These include species from genera such as *Acropora*, *Porites*, and *Favia*, which contribute significantly to reef accretion and habitat complexity (Munasik et al. 2020; Putra et al. 2022). In contrast, soft corals—such as *Sinularia*, *Sarcophyton*, and *Lobophytum*—do not contribute to reef-building but play a vital ecological and chemical role through the production of bioactive metabolites (Changyun et al. 2008; dos Santos et al. 2023). These soft-bodied cnidarians often dominate benthic communities in mesophotic and current-exposed zones, where their secondary metabolites serve both defensive and allelopathic functions.



Figure 1. Examples of coral reefs, Organisms, and Habitats: *Acropora cervicornis* (staghorn coral), B. Dead coral substrate, C. *Sinularia* spp. (soft coral), D. Fleshy macroalgae (unidentified species), E. *Sargassum* spp. (brown algae), F. *Turbinaria* spp. (brown algae)

Indonesia hosts more than 569 coral species belonging to 83 genera, making it one of the most biodiverse coral regions in the world (Asaad et al. 2020; Hadi et al. 2020). These species are distributed across various reef types, including fringing reefs, barrier reefs, atolls, and patch reefs, with extensive coverage in regions such as Raja Ampat, Wakatobi, and the Sunda-Banda Seascape (Ministry of Maritime Affairs and Fisheries 2020). This exceptional richness provides a broad platform to explore species-specific chemical compounds and their biomedical relevance. Notably, some genera endemic or highly abundant in Indonesian waters—such as *Cladiella*, *Nephthea*, and *Paralemnalia*—have already shown pharmacologically significant metabolites, yet remain understudied compared to better-known genera.

Soft corals, particularly those in the subclass Octocorallia, are renowned for their structural plasticity and chemical defense mechanisms. Their internal skeletons are composed of spicules made of calcium carbonate and proteinaceous material, and their tissues are often brightly colored due to the presence of pigments and symbiotic zooxanthellae (Rahman et al. 2011; Varijakzhan et al. 2021). These adaptations not only serve ecological functions but also correlate with the presence of diverse secondary metabolites that contribute to pharmacological activity. In particular, coloration intensity and polyp density have been linked to the expression of specific biosynthetic gene clusters, suggesting a functional relationship between environmental cues and metabolite production.

The diversity of coral reef organisms is not only taxonomic but also biochemical, with each genus or species potentially producing distinct sets of compounds. Such diversity offers immense bioprospecting potential, especially when combined with modern molecular and metabolomic tools. Beyond corals themselves, reef ecosystems support chemically rich taxa such as tunicates, bryozoans, and sponges—many of which are symbiotic or epiphytic and contribute to the reef's chemical ecology. These associations frequently involve horizontal gene transfer and microbial consortia capable of producing complex natural products, which can be leveraged through metagenomic and transcriptomic analyses.

Understanding the taxonomic and ecological diversity of coral reef organisms is essential as a foundation for chemical profiling and pharmacological exploration. It enables the identification of target species and compounds, facilitates sustainable harvesting strategies, and supports conservation priorities aligned with biotechnological innovation. Integrating biodiversity mapping with high-throughput screening platforms may significantly enhance the discovery pipeline for novel marine-derived drugs.

Chemical constituents of coral reefs

The coral reef environment harbors a wide spectrum of bioactive secondary metabolites, offering a promising avenue for pharmacological research. These compounds are synthesized by various reef organisms, particularly soft corals, sponges, and symbiotic microbes (Putnam et al. 2017; Cutolo et al. 2024). These compounds are typically involved in chemical defense, reproduction, and interspecies signaling. The majority are low-molecular-weight, lipophilic molecules, often featuring halogenated moieties or unique carbon skeletons not commonly found in terrestrial metabolites (Ermolenko et al. 2020; Hanafy et al. 2022). The presence of such structural novelty increases the likelihood of discovering new mechanisms of action or drug targets not yet addressed by existing therapeutics.

Understanding the chemical composition of coral reefs, particularly the skeletal structure of hard corals, is of paramount importance. The skeletal structure is primarily composed of aragonite ($CaCO_3$), but also contains trace elements such as magnesium, strontium, and occasionally heavy metals, which may influence both structural integrity and bioavailability of associated compounds. In addition, organic matrices embedded within the coral skeleton can contain glycoproteins, lipids, and phenolic residues, some of which may contribute to pharmacological activities when processed as powders or extracts. These matrices have also been proposed as bioceramic templates in tissue engineering and regenerative medicine, particularly in bone graft substitutes and drug delivery scaffolds. Table 1 provides a synthesis of major bioactive compounds reported from various coral reef organisms and highlights their corresponding pharmacological activities, illustrating the chemical richness and biomedical relevance of reef biodiversity.

Soft corals are known to produce an even more diverse range of secondary metabolites than their hard counterparts. Cembranoid-type diterpenoids are among the most studied compounds isolated from genera such as *Sarcophyton*, *Sinularia*, and *Lobophytum* (Fristiohady et al. 2019). These compounds exhibit a wide array of bioactivities, including cytotoxic, antiviral, and anti-inflammatory properties. Steroidal glycosides and prostaglandins have also been isolated from reef gorgonians and soft corals, often with unique side chains that enhance receptor selectivity and pharmacological potency (Chen et al. 2016). Recent Structure-Activity Relationship (SAR) studies suggest that halogenation and epoxidation at specific carbon positions improve cytotoxic selectivity indices and target binding affinity.

Apart from terpenoids and steroids, nitrogen-containing compounds such as alkaloids, nucleosides, and amino acid derivatives are prevalent in reef-associated sponges and tunicates. For example, some sponge-derived alkaloids have shown activity against *Plasmodium* species and multidrug-resistant bacteria (Nusaly et al. 2024). Other nitrogenous compounds, such as brominated tyrosine derivatives, are believed to originate from symbiotic microbes and are often associated with potent cytotoxic or neuromodulatory effects. Some of these compounds have advanced to preclinical testing stages, highlighting their translational potential despite the challenge of sustainable supply.

Marine saponins, while less frequently studied, have also been isolated from echinoderms and coralline algae in reef environments. These amphipathic glycosides exhibit hemolytic, immunomodulatory, and antifungal properties. Flavonoids and polyphenolic compounds, though more commonly associated with plants, have been detected in coral reef macroalgae and contribute to antioxidant activity (Pirian et al. 2017; Avila-Romero et al. 2022). These compounds are often

involved in photoprotection and stress responses and may be harnessed for cosmeceutical or nutraceutical applications. Interestingly, some macroalgal flavonoids have shown synergistic effects when combined with marine alkaloids, suggesting combinatorial approaches for drug development.

The chemical ecology of coral reefs is further enriched by microbial symbionts, including bacteria, archaea, and fungi, which often reside in coral mucus or tissues. These microbes contribute to the synthesis of complex polyketides, non-ribosomal peptides, and hybrid molecules that are difficult to obtain from other environments. Metagenomic studies have begun to uncover the biosynthetic gene clusters responsible for these metabolites, offering promising avenues for sustainable biosynthesis and drug development (Cooper et al. 2014). Coupled with genome mining and synthetic biology, these insights have paved the way for heterologous expression of coral reef-derived compounds in model organisms such as *Streptomyces* and *E. coli*.

In summary, coral reefs' chemical constituents encompass a structurally diverse and pharmacologically rich array of molecules. These include major classes such as terpenoids, steroids, alkaloids, flavonoids, saponins, and prostaglandins, each with distinct biological activities and therapeutic relevance. Understanding the origin, structure, and bioactivity of these compounds is essential for guiding bioprospecting efforts and identifying lead candidates for further pharmacological evaluation. Future efforts should prioritize the integration of ecological metadata, omics technologies, and cheminformatics to optimize compound discovery and sustainable utilization.

Major bioactive compound classes

Terpenoids

Terpenoids are among the most frequently reported secondary metabolites in coral reef organisms, particularly soft corals such as *Sarcophyton*, *Sinularia*, and *Lobophytum*. These compounds are synthesized through the mevalonate or Methylerythritol Phosphate (MEP) pathways and typically serve as chemical defenses against predators, fouling organisms, or microbial pathogens (Fristiohady et al. 2019). Cembranoids, a subclass of diterpenoids, are especially abundant in soft corals, often characterized by complex ring structures with epoxide or furan moieties, and exhibit a wide range of biological activities, including anti-inflammatory, cytotoxic, and antimicrobial effects.

Table 1. Summary of bioactive compounds and pharmacological properties of coral reef organisms

Organism/source	Major compounds	Compound class	Pharmacological properties	References
Sarcophyton spp. (Soft coral)	Cembranoids, diterpenes	Terpenoids	Anti-inflammatory, cytotoxic, antibacterial	Cooper et al. 2014; Fristiohady et al. 2019
Sinularia spp. (Soft coral)	Steroids, terpenoids	Steroids, Terpenoids	Antibacterial, antifungal, anti-inflammatory	Mayer et al. 2013
Padina australis (Brown alga)	Phlorotannins, polyphenols	Flavonoids, Polyphenols	Antioxidant, antidiabetic	Pirian et al. 2017
Sargassum polycystum (Brown alga)	Fucoidans, sulphated polysaccharides	Polysaccharides	Antidiabetic, antioxidant, antimicrobial	Pirian et al. 2017; Avila-Romero et al. 2022
Haliclona sp. (Sponge)	Manzamine A, alkaloids	Alkaloids	Antimalarial, anticancer, anti-parasitic	Cooper et al. 2014
Soft coral-associated fungi	Polyketides, terpenes	Microbial metabolites	Cytotoxic, antibacterial	Karthikeyan et al. 2022
Sea cucumber (*Holothuroidea*)	Triterpene glycosides	Saponins	Immunomodulatory, antihypertensive	Cutolo et al. 2024
Symbiotic bacteria (*Pseudoalteromonas*)	Alkaloids, antimicrobial peptides	Microbial metabolites	Antibacterial, antifouling	Song et al. 2018; Karthikeyan et al. 2022
Gorgonians (*Eunicella* spp.)	Sesquiterpenes, diterpenes	Terpenoids	Anti-inflammatory, antimicrobial	Mayer et al. 2013
Zoanthus spp.	Zoanthamines	Alkaloids	Cytotoxic, neuroactive	Cooper et al. 2014
Pseudoalteromonas spp. (Mucus bacteria)	Bromoalterochromides, tambjamines	Microbial metabolites	Antibacterial, anticancer	Karthikeyan et al. 2022
Didemnum spp. (Tunicate)	Cyclic peptides, didemnins	Peptides, Alkaloids	Antiviral, cytotoxic	Cooper et al. 2014; Karthikeyan et al. 2022
Gracilaria spp. (Red alga)	Sulfated polysaccharides, agarans	Polysaccharides	Antioxidant, anticoagulant	Avila-Romero et al. 2022
Caulerpa spp. (Green alga)	Caulerpenyne, carotenoids	Terpenoids, Carotenoids	Antiviral, hepatoprotective	Fristiohady et al. 2019
Sea urchin (*Diadema* spp.)	Echinochrome A, polyhydroxynaphthoquinones	Quinones	Antioxidant, cardioprotective	Cutolo et al. 2024
Starfish (*Acanthaster planci*)	Saponins, steroidal glycosides	Saponins, Steroids	Cytotoxic, antifeedant	Karthikeyan et al. 2022
Bryozoans (*Bugula neritina*)	Bryostatins (macrolides)	Macrolides	Anticancer, memory enhancement	Cooper et al. 2014
Cyanobacteria (*Lyngbya majuscula*)	Lyngbyatoxins, aplysiatoxins	Toxins, Alkaloids	Antitumor, neurotoxic	Karthikeyan et al. 2022

Many terpenoids isolated from corals have highly oxygenated or epoxidized ring structures, contributing to their high reactivity and biological specificity (Cooper et al. 2014). Sarcophytol A, for instance, is a cembranoid diterpenoid known for its antitumor properties, while *sinulariolide* and *lobophytolide* have demonstrated significant anti-inflammatory and neuroprotective activities (Chen et al. 2016). More recent findings have suggested that some diterpenes also modulate ion channels and apoptosis pathways, making them candidates for neurodegenerative disease research. Due to their lipophilic nature and membrane-targeting properties, terpenoids are not only considered promising leads in drug development, but are also actively screened in anticancer, antiviral, and antiparasitic pipelines.

Steroids

Steroidal compounds derived from reef organisms differ structurally from those of terrestrial sources. Marine steroids with their unusual side chains, sulfated moieties, or halogen substitutions engage in unique and fascinating interactions that alter their interaction with biological targets (Ermolenko et al. 2020). These structural differences can enhance receptor specificity or modulate immune response in ways that continue to intrigue researchers. In addition, some marine steroids function as signaling molecules that regulate microbial symbiosis and coral immune homeostasis.

The diversity of marine steroids from coral reef sponges and gorgonians, including classes such as polyhydroxylated sterols, secosteroids, and glycosylated pregnanes, is a source of inspiration for researchers. Many of these steroids exhibit anti-inflammatory, cytotoxic, or antiviral properties (Karthikeyan et al. 2022). Some reef-derived steroids also act as inhibitors of enzymes involved in steroidogenesis or tumor progression. Steroidal metabolites like sarcosteroids and gibberoketosterols have shown inhibitory activity against COX enzymes and estrogen receptors, indicating potential use in hormonal disorders and cancer therapy. This rich diversity and the potential for novel applications in immunomodulation, hormone regulation, and endocrine therapy are motivating factors for further exploration in this field.

Nitrogen-containing compounds

Nitrogenous compounds in coral reef systems include alkaloids, amino acid derivatives, brominated tyrosines, nucleosides, and nitrogenous heterocycles. Reef-associated sponges, tunicates, and microbial symbionts commonly produce these compounds (Nusaly et al. 2024). Alkaloids are particularly valuable for their broad pharmacological spectra, including neurotoxicity, antimicrobial activity, and enzyme inhibition. Their structural diversity includes polycyclic frameworks, spiro systems, and halogenated indoles, making them attractive for CNS drug development.

Marine alkaloids from reef organisms often have halogen substitutions (e.g., bromine or chlorine), which are rare in terrestrial metabolites. For example, *bastadins* from sponges and *lamellarins* from ascidians exhibit anticancer and antiviral effects, respectively. Nitrogen-containing metabolites also include nucleoside analogs such as *cytarabine*, which, although originally isolated from deep-sea sponges, reflect the therapeutic potential of reef microbial analogs. This emphasis on the potential of these compounds can inspire hope for the future of pharmacology. Additionally, bromotyrosines from sponges have shown promising anti-inflammatory and antimalarial effects (Varijakzhan et al. 2021). Ongoing synthetic biology approaches are exploring the heterologous expression of alkaloid biosynthetic pathways to overcome the limitations of natural harvest and low yield.

Other compounds: Flavonoids, Saponins, and Prostaglandins

While terpenoids, steroids, and alkaloids dominate marine chemical studies, other compound classes such as flavonoids, saponins, and prostaglandins are gaining attention for their diverse bioactivities. Flavonoids are commonly found in reef-associated macroalgae, such as *Sargassum* and *Padina*, and function primarily as antioxidants and UV protectants (Avila-Romero et al. 2022). These compounds may have cosmeceutical or nutraceutical applications due to their roles in mitigating oxidative stress and inflammation. Recent studies have demonstrated their ability to modulate MAPK and NF-κB signaling, suggesting broader anti-aging and anti-inflammatory relevance.

Saponins, amphipathic glycosides with detergent-like properties, are occasionally isolated from echinoderms and coralline algae in reef environments. They exhibit hemolytic, cytotoxic, and antifungal effects and may modulate immune responses (Zhao et al. 2024). Due to their membrane-disrupting capabilities, saponins are being explored as vaccine adjuvants and anti-parasitic agents. Moreover, some marine saponins have demonstrated selective toxicity against cancer cells, likely due to their interactions with cholesterol-rich membranes.

Prostaglandin-like compounds, notably from gorgonians and soft corals, mimic mammalian eicosanoids in structure and function. These include prostaglandins A_2 and E_2 analogs, which exhibit smooth muscle relaxation, anti-inflammatory, and antithrombotic properties (Mayer et al. 2013). Their presence in marine organisms reflects the convergent evolution of chemical signaling and underscores their therapeutic relevance. Several coral-derived prostanoids are under investigation for cardiovascular and reproductive health applications.

Collectively, these compound classes reflect the immense chemical richness of coral reef ecosystems and their multifaceted contributions to biomedical research. Understanding their biosynthetic origins, ecological functions, and pharmacological effects is crucial for advancing marine drug discovery sustainably and ethically. To accelerate translational outcomes, interdisciplinary collaboration among chemists, marine biologists, pharmacologists, and conservationists is essential.

PHARMACOLOGICAL ACTIVITIES OF CORAL-DERIVED COMPOUNDS

Antibacterial and antiviral activity

Coral reef organisms are prolific sources of antimicrobial compounds with activity against a broad range of bacterial and viral pathogens. Various secondary

metabolites isolated from soft corals, sponges, and their symbiotic microorganisms have shown potent inhibitory effects on Gram-positive and Gram-negative bacteria, as well as on several viral families (Ermolenko et al. 2020; Hanafy et al. 2022). These bioactive compounds are of particular interest in the search for alternatives to conventional antibiotics, especially amid rising antimicrobial resistance and the global threat of neglected tropical diseases.

Soft corals, especially those belonging to the genera *Sarcophyton* and *Sinularia*, are known for producing terpenoids and cembranoids with broad-spectrum antibacterial activity. Sarcophytol A, for instance, has demonstrated inhibitory effects against *Staphylococcus aureus* and *Escherichia coli*, with proposed mechanisms involving membrane disruption and inhibition of protein synthesis (Fristiohady et al. 2019). Similarly, lobophytolide-type diterpenes from *Lobophytum* species have shown activity against Methicillin-Resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (Chen et al. 2016). These findings underscore the potential of coral-derived terpenoids as scaffolds for the development of next-generation antibiotics.

Marine sponges are another rich source of antibacterial agents. Alkaloids such as agelasines, manzamines, and related nitrogen-containing compounds, originally isolated from reef-associated sponges, exhibit significant inhibitory activity against *Mycobacterium tuberculosis*, *Helicobacter pylori*, and multidrug-resistant strains of *Salmonella* (Cooper et al. 2014). These metabolites act through multiple mechanisms, including inhibition of DNA synthesis, disruption of membrane integrity, and interference with bacterial enzyme systems. Importantly, some of these alkaloids retain efficacy against strains that exhibit resistance to β-lactams and fluoroquinolones.

In addition to their antibacterial potential, coral reef organisms also produce compounds with notable antiviral properties. Brominated tyrosine derivatives, isolated from both sponges and soft corals, have been reported to suppress replication of Herpes Simplex Virus (HSV), dengue virus, and Human Immunodeficiency Virus (HIV) (Mayer et al. 2013). For example, pseudopterosins, a group of diterpene glycosides from Caribbean gorgonians, inhibit viral entry and reduce inflammation in infected tissues. This dual antiviral and anti-inflammatory action is especially beneficial for the treatment of viral diseases with strong inflammatory responses, such as dengue, hepatitis, and COVID-19.

Coral-associated microbes, especially actinobacteria and fungi, have gained attention as sources of novel antimicrobial agents. These symbionts produce polyketides, macrolides, and depsipeptides with antimicrobial activity equal to or superior to that of their host. Recent metagenomic studies have identified cryptic Biosynthetic Gene Clusters (BGCs) from coral microbiomes that could be harnessed for novel antibiotic discovery (Karthikeyan et al. 2022). These microbial consortia offer a promising avenue for scalable and sustainable compound production.

However, despite extensive in vitro bioactivity reports, only a few coral-derived antimicrobials have progressed to preclinical or clinical development. This gap is primarily due to challenges in compound isolation, low natural abundance, synthesis complexity, and incomplete toxicity profiling. Nonetheless, the antibacterial and antiviral activities of coral-derived compounds continue to offer valuable scaffolds for pharmacological innovation.

Future directions should prioritize in vivo efficacy testing, pharmacokinetic and toxicity assessments, and elucidation of molecular mechanisms of action. Structure-Activity Relationship (SAR) studies and medicinal chemistry optimization are also crucial for improving potency and selectivity. Moreover, exploring synergistic interactions between coral-derived compounds and existing antimicrobial agents could enhance efficacy and help combat resistant infections.

Anti-inflammatory activity

Inflammation plays a pivotal role in the pathogenesis of various acute and chronic diseases, including arthritis, cardiovascular disorders, neurodegeneration, and cancer. Coral reef organisms, particularly soft corals and sponges, have yielded numerous compounds with significant anti-inflammatory properties. Many of these act through the inhibition of key pro-inflammatory mediators, such as nitric oxide (NO), prostaglandins (e.g., PGE_2), cytokines, and nuclear factor-kappa B (NF-κB) signaling pathways (Chen et al. 2016; Fristiohady et al. 2019). These mechanisms are comparable to those targeted by conventional anti-inflammatory drugs but often involve structurally novel compounds with potential for reduced side effects.

Cembranoid diterpenes from *Sarcophyton* species are among the most studied coral-derived anti-inflammatory agents. Compounds such as sarcophytolide B have been shown to downregulate the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), key enzymes responsible for the synthesis of NO and PGE_2, respectively (Fristiohady et al. 2019). These effects are believed to be mediated through the suppression of mitogen-activated protein kinase (MAPK) and NF-κB signaling cascades, both central to the inflammatory response.

Similarly, lobophytolides and sinulariolides from *Lobophytum* and *Sinularia* species have demonstrated the ability to reduce pro-inflammatory cytokine secretion, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), in lipopolysaccharide (LPS)-stimulated macrophages (Cooper et al. 2014; Chen et al. 2016). This suggests their potential application in treating immune-mediated conditions such as rheumatoid arthritis and inflammatory bowel disease.

Marine steroids with unique side chains, isolated from gorgonians and reef-associated sponges, also exhibit notable immunomodulatory effects. Compounds such as 24-methylenecholesterol and pregnane derivatives have been reported to inhibit IL-1β and interferon-gamma (IFN-γ) production in vitro (Mayer et al. 2013; Kang et al. 2019). Owing to their partial structural resemblance to corticosteroids, these marine-derived steroids are being explored as alternative modulators with potentially improved pharmacokinetics and safety.

Beyond purified compounds, whole-tissue extracts of soft corals have also shown anti-inflammatory effects in vivo. For instance, methanolic extracts of *Sarcophyton glaucum* significantly reduced paw edema and leukocyte infiltration in carrageenan-induced inflammation models (dos Santos et al. 2023). These findings support traditional coastal uses of coral-based materials for wound healing and the treatment of inflammatory ailments.

Despite these promising results, few coral-derived anti-inflammatory agents have advanced beyond preclinical testing. Limitations include insufficient pharmacodynamic data, incomplete toxicity profiling, and a lack of long-term safety evaluations. Nevertheless, the structural diversity, multi-target capacity, and marine origin of these compounds make them promising candidates for the development of novel anti-inflammatory therapeutics. Future research should prioritize bioavailability enhancement, target specificity, and translational studies to advance these leads into clinical pipelines.

Cytotoxic and anticancer activity

Among the various pharmacological effects of coral reef-derived compounds, their cytotoxicity against cancer cells is one of the most intensively explored. Numerous secondary metabolites isolated from soft corals, sponges, and gorgonians have shown potent antiproliferative effects against a broad spectrum of human tumor cell lines, including leukemia, breast, lung, liver, and colon cancers (Fristiohady et al. 2019; Ermolenko et al. 2020). These compounds represent promising scaffolds for novel chemotherapeutic agents, particularly those targeting drug-resistant malignancies.

Cembranoid diterpenes such as sarcophytolide A and sinulariolide, isolated from *Sarcophyton* and *Sinularia* species, are well-documented for inducing apoptosis in cancer cells. Their mechanisms of action involve mitochondrial membrane depolarization, caspase cascade activation, and downregulation of anti-apoptotic proteins such as Bcl-2 (Cooper et al. 2014; Fristiohady et al. 2019). Notably, these compounds demonstrate preferential toxicity toward malignant cells, with limited impact on healthy cells, highlighting their therapeutic index.

Other bioactive diterpenes such as lobophytolides and isosarcophytoxides, primarily from soft corals, exhibit cytostatic effects on hepatocellular carcinoma (HepG2), human leukemia (HL-60), and breast cancer (MCF-7) cell lines. These compounds often induce cell cycle arrest at the G1 or G2/M phases, indicating possible DNA damage or mitotic inhibition mechanisms (Chen et al. 2016). Such activity supports their potential role as adjuvants in combination therapies with standard chemotherapeutic drugs.

Alkaloids derived from marine sponges, particularly manzamine A, a β-carboline compound, have also demonstrated exceptional anticancer activity. Manzamine A exhibits nanomolar-range cytotoxicity against pancreatic, colorectal, and prostate cancer cells, acting via inhibition of Cyclin-Dependent Kinases (CDKs) and modulation of the Wnt/β-catenin pathway (Cooper et al. 2014; Karthikeyan et al. 2022). Given the limited efficacy of many conventional alkaloids due to resistance mechanisms, the unique structures of marine-derived alkaloids offer alternatives for overcoming therapeutic resistance.

Additionally, prostaglandin analogs isolated from gorgonian corals like *Pseudopterogorgia* exhibit anti-angiogenic and anti-metastatic effects. These compounds suppress Vascular Endothelial Growth Factor (VEGF) signaling and Matrix Metalloproteinase (MMP) activity, thereby inhibiting tumor neovascularization and invasion (Mayer et al. 2013). Such mechanisms are critical for impeding the progression of solid tumors.

Importantly, several coral-derived compounds have demonstrated efficacy against Multidrug-Resistant (MDR) cancer cell lines, including those overexpressing P-glycoprotein (P-gp) or other ATP-Binding Cassette (ABC) transporters. This indicates the potential to bypass common resistance mechanisms, a major limitation of current chemotherapies. Synergistic effects with standard drugs such as doxorubicin and cisplatin have also been reported, though pharmacokinetic and safety data remain limited.

Despite strong in vitro and some in vivo evidence, the clinical development of coral-based cytotoxic agents is still in its infancy. Major obstacles include low compound yields, cytotoxicity to normal cells at higher doses, and challenges in formulation and delivery. However, recent advances in biosynthetic engineering, semi-synthetic derivatization, and nanocarrier-based drug delivery offer realistic pathways for clinical translation.

Antioxidant properties

Oxidative stress, driven by the overproduction of Reactive Oxygen Species (ROS), contributes significantly to the pathophysiology of various chronic diseases, including neurodegenerative disorders, cardiovascular disease, cancer, and age-related conditions. Antioxidants neutralize ROS and protect essential cellular biomolecules—lipids, proteins, and nucleic acids—from oxidative damage. Coral reef organisms, particularly reef-associated macroalgae, soft corals, and microbial symbionts, are rich sources of natural antioxidant compounds with diverse mechanisms of action (Pirian et al. 2017; Avila-Romero et al. 2022). These include radical scavengers, metal ion chelators, enzyme modulators, and enhancers of endogenous antioxidant systems.

Flavonoids and polyphenols isolated from reef macroalgae such as *Sargassum polycystum* and *Padina australis* have demonstrated strong radical-scavenging activity in vitro, particularly through DPPH and ABTS assays (Pirian et al. 2017). Key compounds such as catechins, kaempferol derivatives, and phlorotannins exhibit high redox potential, attributable to their hydroxyl-rich structures, allowing them to effectively prevent lipid peroxidation and oxidative protein damage. Owing to their safety and bioactivity, these molecules are increasingly being explored in functional foods, nutraceuticals, and anti-aging cosmeceuticals.

Soft coral extracts also possess significant antioxidant potential. Methanolic extracts of *Sarcophyton glaucum* and *Sinularia flexibilis* have been shown to reduce intracellular ROS levels and improve fibroblast viability following

hydrogen peroxide-induced oxidative stress (dos Santos et al. 2023). These effects are associated with terpenoids, sterols, and phenolic compounds that may activate redox-sensitive pathways, particularly Nrf2/ARE and MAPK, which govern the expression of endogenous antioxidant enzymes.

Beyond crude extracts, several purified marine compounds have demonstrated targeted antioxidant effects. Marine steroids and prostaglandin-like molecules from coral reef organisms have been reported to suppress lipid peroxidation and enhance glutathione (GSH) levels in cellular systems (Mayer et al. 2013). Some also induce the upregulation of Superoxide Dismutase (SOD), catalase, and Glutathione Peroxidase (GPx), thereby strengthening the cellular antioxidant defense system.

These properties are particularly valuable in contexts where oxidative stress is a central disease driver. In neurodegenerative disease models, antioxidant-rich extracts from *Padina* species have shown protective effects against β-amyloid-induced neurotoxicity, relevant to Alzheimer's disease. In metabolic syndrome models, coral-derived antioxidants have demonstrated potential to reduce oxidative lipid peroxidation and improve insulin sensitivity, suggesting roles in diabetes management.

While many antioxidant effects have been validated in vitro, further in vivo studies are essential to assess bioavailability, metabolic stability, and therapeutic windows. Advanced delivery systems—such as lipid-based nanoparticles, emulsions, or hydrogels—could enhance the clinical potential of coral-derived antioxidants. Given their chemical diversity, multifunctionality, and marine origin, these compounds offer unique advantages as candidates for future antioxidant therapies.

Neuroprotective effects

Neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's diseases, are characterized by progressive synaptic dysfunction and neuronal cell death, commonly driven by oxidative stress, chronic neuroinflammation, excitotoxicity, mitochondrial dysfunction, and protein aggregation. Bioactive compounds from coral reef organisms have shown significant potential in modulating these pathological processes (Mayer et al. 2013; dos Santos et al. 2023). The structural diversity of these marine metabolites allows for multimodal actions, including antioxidant defense, anti-inflammatory regulation, and neurochemical modulation, making them attractive candidates for neurotherapeutics.

Terpenoids such as sinulariolide and lobophytolide, isolated from *Sinularia* and *Lobophytum* species, have demonstrated neuroprotective effects in vitro by reducing neuronal apoptosis and suppressing pro-inflammatory cytokine release (Chen et al. 2016). These compounds inhibit the activation of microglia and astrocytes—key mediators of neuroinflammation in response to injury or β-amyloid accumulation—thereby mitigating the production of neurotoxic mediators such as TNF-α and IL-1β. Their ability to modulate the NF-κB, MAPK, and JAK/STAT signaling pathways suggests a dual role in controlling both oxidative stress and neuroinflammatory cascades in the Central Nervous System (CNS).

Flavonoids and polyphenolic compounds derived from reef-associated macroalgae, such as *Padina australis*, have been investigated for their efficacy in counteracting β-amyloid toxicity in neuronal models. These compounds prevent amyloid-β peptide aggregation, preserve mitochondrial membrane potential, and restore neuronal viability, highlighting their potential application in Alzheimer's disease therapy (Gan et al. 2019; Avila-Romero et al. 2022). Molecular docking and in silico analyses have also suggested that these algal flavonoids may interact with tau kinases and acetylcholinesterase, offering broader protective effects on cognitive functions.

Marine steroids and prostaglandin-like molecules from soft corals and reef gorgonians have also emerged as neuroactive scaffolds. Certain marine-derived steroids act as neurosteroids, modulating GABA_A and NMDA receptors and influencing neural excitability, with potential applications in epilepsy, anxiety, and neurodevelopmental disorders (Mayer et al. 2013). These activities reflect a capacity to influence synaptic transmission and neuroplasticity, placing coral steroids within a growing category of natural CNS modulators.

In addition to isolated compounds, several coral and macroalgae extracts have demonstrated nootropic and cognitive-enhancing effects in vivo. For instance, ethanolic extracts of *Sargassum* and *Padina* species have improved memory and spatial learning in scopolamine-induced models of amnesia, accompanied by increased hippocampal acetylcholine levels and reduced oxidative stress markers. These findings suggest the feasibility of developing coral reef-derived nutraceuticals for cognitive health and neurodegenerative disease prevention.

Despite these promising findings, clinical translation remains hampered by challenges such as low oral bioavailability, unknown Blood-Brain Barrier (BBB) permeability, and limited long-term toxicity data. Future research should prioritize pharmacokinetic profiling, in vivo BBB transport studies, and target deconvolution to identify precise receptor or enzyme interactions. Given the multifactorial nature of neurodegenerative diseases, marine-derived compounds with pleiotropic mechanisms—especially those combining antioxidant, anti-inflammatory, and neurotransmitter-modulating properties—may hold superior therapeutic value compared to single-target agents.

Antidiabetic activity

The global burden of diabetes mellitus continues to rise, with type 2 diabetes accounting for over 90% of cases worldwide. Oxidative stress, chronic inflammation, and insulin resistance are recognized as key pathogenic mechanisms. This complex interplay of metabolic dysregulation has fueled interest in natural compounds that can modulate glucose metabolism, enhance insulin signaling, and preserve pancreatic β-cell function. Several coral reef-derived organisms, particularly macroalgae and sponges, have been reported to produce such antidiabetic compounds (Pirian et al. 2017; Avila-Romero et al. 2022). These bioactive substances exert their effects through multi-target mechanisms, including inhibition of carbohydrate-digesting

enzymes, antioxidant activity, anti-inflammatory pathways, and insulin-mimetic or insulin-sensitizing actions.

Macroalgae such as *Sargassum polycystum* and *Padina australis*, which are commonly found in reef-associated environments, contain bioactive polysaccharides (e.g., fucoidans), polyphenols, flavonoids, and phlorotannins with α-amylase and α-glucosidase inhibitory activity (Pirian et al. 2017). These enzymes catalyze the hydrolysis of dietary polysaccharides into absorbable monosaccharides. Their inhibition slows postprandial glucose absorption and reduces glycemic spikes, mirroring the pharmacological effect of α-glucosidase inhibitors such as acarbose but with a potentially better gastrointestinal safety profile. Thus, coral reef macroalgae may act as natural functional food ingredients or adjunct therapies for glycemic control.

In vitro and in vivo studies have demonstrated that extracts from *Sargassum* can improve insulin sensitivity, reduce fasting blood glucose levels, and prevent weight gain in diabetic animal models. These effects are attributed to compounds such as fucoidans, sulphated polysaccharides, and phloroglucinol derivatives, which also modulate inflammatory cytokines (e.g., TNF-α, IL-6) and oxidative stress markers such as Malondialdehyde (MDA) (Avila-Romero et al. 2022). Mechanistically, some of these compounds may upregulate GLUT4 expression and activate Insulin Receptor Substrate (IRS) signaling, supporting their utility in metabolic regulation. These findings underscore the immense potential of coral-associated seaweeds to serve as both preventive and therapeutic agents for metabolic disorders.

Beyond algae, sponge-derived compounds such as manzamines, agelasines, and brominated alkaloids have also demonstrated antidiabetic activity. These compounds may exert insulin-sensitizing effects through activation of AMP-activated Protein Kinase (AMPK), a central regulator of glucose and lipid metabolism (Cooper et al. 2014). AMPK activation leads to increased glucose uptake, fatty acid oxidation, and inhibition of hepatic gluconeogenesis—key processes dysregulated in insulin-resistant states. Such mechanism-driven interventions are particularly attractive in the treatment of type 2 diabetes, where conventional therapies often fail to address multiple pathological nodes.

Additional effects observed in coral-derived extracts include inhibition of Advanced Glycation End-products (AGEs) formation, improvement of lipid profiles, and protection of endothelial function. For instance, polyphenol-rich extracts from *Padina* species reduced protein glycation, enhanced Superoxide Dismutase (SOD) activity, and lowered triglyceride levels in streptozotocin-induced diabetic rats, indicating systemic benefits beyond glycemic control. This pleiotropic pharmacology aligns with current trends in diabetes management, which prioritize cardiovascular risk reduction and organ protection.

While preclinical data are promising, clinical translation is still constrained by variability in extract composition, lack of standardized dosing, limited pharmacokinetic data, and incomplete toxicity profiling. Future work should prioritize standardization of bioactive fractions, detailed mechanistic studies in diabetic models, and well-designed pilot clinical trials to validate efficacy and safety in human populations. Nonetheless, coral reef-derived compounds represent a novel and underutilized reservoir for the development of antidiabetic agents with multifaceted and integrative therapeutic potential.

Other pharmacological activities

Beyond antibacterial, anti-inflammatory, cytotoxic, neuroprotective, antioxidant, and antidiabetic effects, coral reef-derived compounds have also been associated with a wide range of additional yet underexplored pharmacological activities. These include anti-parasitic, anticoagulant, antifouling, immunomodulatory, and wound-healing effects—all of which offer novel therapeutic avenues in the treatment of infectious, vascular, autoimmune, and dermatological conditions (Mayer et al. 2013; Fristiohady et al. 2019; Karthikeyan et al. 2022). The remarkable structural and functional diversity of marine secondary metabolites allows them to interact with varied molecular targets, making coral reef organisms a versatile reservoir for innovative drug discovery.

Several studies have reported anti-parasitic activity from coral reef-associated sponges and their alkaloid derivatives, particularly manzamine A. This β-carboline alkaloid, originally isolated from *Haliclona* sponges, has shown potent efficacy against *Plasmodium falciparum* and *Leishmania* species (Cooper et al. 2014). These compounds disrupt mitochondrial membrane potential and nucleic acid synthesis in protozoan parasites, highlighting their promise for combating neglected tropical diseases such as malaria and leishmaniasis. The need for new anti-parasitics due to emerging resistance further amplifies the relevance of such marine-derived leads.

Polysaccharides and sulfated metabolites from macroalgae and coral reef echinoderms have demonstrated anticoagulant properties by targeting key enzymes in the coagulation cascade. These include thrombin and factor Xa, with some compounds also enhancing antithrombin III activity (Qin et al. 2023). Functionally, these molecules mimic the pharmacodynamics of heparin but may offer better biocompatibility, lower immunogenicity, and reduced hemorrhagic risk, making them attractive candidates for safer anticoagulant therapies.

Antifouling compounds from soft corals and gorgonians are also gaining interest—not only for preventing marine biofouling on submerged surfaces but also for their potential to inhibit bacterial biofilm formation on medical implants. For instance, terpenoid derivatives from *Sinularia* and *Pseudopterogorgia* have shown ability to interfere with quorum sensing and microbial adhesion. These properties are especially relevant in addressing device-associated infections and multidrug-resistant biofilm-producing bacteria. The dual applicability of these agents in both environmental and medical contexts underscores their strategic value in sustainable bioprospecting.

Immunomodulatory effects of coral-derived compounds, particularly marine steroids and terpenoids, have been documented in vitro and in vivo. These compounds modulate cytokine profiles—such as reducing IL-6 and TNF-α or enhancing IL-10—and affect the function of immune effector cells including T-cells and macrophages

(Mayer et al. 2013; Kang et al. 2019). Such properties suggest potential for treating autoimmune disorders, inflammatory syndromes, and even as adjuvants in next-generation vaccines.

Wound-healing activity is another promising but relatively underreported area. Topical application of coral and macroalgal extracts in animal models has been associated with accelerated epithelialization, increased collagen deposition, and reduced local inflammation. These effects may be mediated by a synergistic combination of antioxidant, anti-inflammatory, and angiogenic compounds, supporting their potential development as bioactive ingredients in regenerative medicine and dermatological formulations.

Although these activities are currently peripheral in the landscape of marine pharmacology, they represent a rich source of multifunctional bioactivities. Continued exploration, mechanistic studies, and preclinical validation could lead to new therapeutic classes with broad-spectrum applications. Expanding the research focus beyond conventional endpoints may unlock the full biomedical potential of coral reef ecosystems. Table 2 summarizes the principal bioactive compound classes from coral reef sources, including their pharmacological effects and known mechanisms of action, providing a classification-based perspective on coral-derived pharmacology.

ETHNOPHARMACOLOGY AND TRADITIONAL USES

Cultural use of coral reef organisms in traditional medicine

Coastal and island communities in tropical regions have long relied on coral reef ecosystems not only for food and livelihood but also for traditional medicine. Marine organisms—including soft corals, sponges, algae, echinoderms, and mollusks—have been used to treat a variety of ailments, from skin infections to internal inflammations (Fristiohady et al. 2019; Cutolo et al. 2024). Such medicinal knowledge is deeply embedded in local cosmologies and subsistence practices, and is often passed down orally across generations through informal apprenticeship or ritualized knowledge transfer.

In Indonesia, for example, extracts from soft corals are occasionally used in coastal herbal medicine to treat wounds and skin rashes. They are often mixed with coconut oil or applied directly in raw or dried form. Healers in coastal areas of Maluku and East Nusa Tenggara commonly apply these extracts for skin disorders, particularly in fishing communities with high exposure to marine abrasions and infections. Although such uses are often undocumented scientifically, anecdotal reports persist in communities along the eastern archipelago, where marine biodiversity is exceptionally rich. The rationale for these applications is often linked to the belief that organisms exposed to harsh marine environments possess powerful protective substances transferable to humans.

Table 2. Major classes of bioactive compounds from coral reef organisms, their pharmacological activities, and mechanisms of action

Compound class	Example organisms	Representative compounds	Pharmacological activities	Mechanisms of action	References
Terpenoids	*Sarcophyton*, *Sinularia*	Sarcophytol A, Sinulariolide	Anti-inflammatory, cytotoxic, neuroprotective	COX-2 inhibition, apoptosis induction, NF-κB suppression	Chen et al. 2016; Fristiohady et al. 2019
Steroids	Gorgonians, soft corals	24-methylenecholesterol, pregnane types	Anti-inflammatory, immunomodulatory	Cytokine modulation, steroid receptor interaction	Mayer et al. 2013; Ermolenko et al. 2020
Alkaloids	Sponges, tunicates	Manzamine A, bromotyrosines	Antibacterial, anticancer, antiparasitic	DNA synthesis inhibition, mitochondrial disruption	Cooper et al. 2014; Karthikeyan et al. 2022
Flavonoids & Polyphenols	*Padina*, *Sargassum*	Kaempferol, catechins, phlorotannins	Antioxidant, anti-aging, neuroprotective, antidiabetic	ROS scavenging, MAPK/Nrf2 pathway activation	Pirian et al. 2017; Avila-Romero et al. 2022
Saponins	Sea cucumber, starfish	Holothurin A, echinoside A	Immunomodulatory, antifungal, cytotoxic	Membrane disruption, immune cell stimulation	Karthikeyan et al. 2022; Cutolo et al. 2024
Prostaglandins	Soft corals, gorgonians	PGA_2, PGE_2 analogs	Anti-inflammatory, antiangiogenic, vasomodulatory	VEGF/MMP inhibition, smooth muscle modulation	Mayer et al. 2013
Polysaccharides	*Sargassum*, *Gracilaria*	Fucoidans, agarans	Antioxidant, anticoagulant, antidiabetic	α-glucosidase inhibition, anti-inflammatory cytokine regulation	Pirian et al. 2017; Avila-Romero et al. 2022
Microbial metabolites	*Pseudoalteromonas*, fungi	Bromoalterochromides, polyketides	Antibacterial, cytotoxic, antifouling	Ribosomal inhibition, quorum sensing interference	Cooper et al. 2014; Karthikeyan et al. 2022

Sponge extracts are also traditionally known to possess antiseptic and anti-inflammatory properties. In some communities, sponge tissue is boiled, and the water is used to bathe inflamed areas or rashes. This practice is typically performed in the early stages of skin infection, often accompanied by verbal incantations or prayer rituals to enhance efficacy. Similar applications exist for certain marine mollusks, where shell powder is sometimes used as a topical drying agent, believed to accelerate wound healing. In coastal Central Sulawesi, powdered mollusk shell is also used to reduce inflammation in boils and skin lesions.

Macroalgae, such as *Sargassum* and *Gracilaria*, are more widely documented in traditional practices. *Sargassum* spp., in particular, are commonly used in Chinese and Southeast Asian folk medicine to reduce swelling, alleviate thyroid disorders, and detoxify the body (Liu et al. 2012; Anastyuk et al. 2017). Local healers in coastal Java and Sulawesi often prepare decoctions from dried brown algae to treat fever, fatigue, or joint pain. The use of these algae is often seasonal, aligned with coastal harvesting cycles, and their processing may involve sun-drying, boiling, and combination with other herbal ingredients.

In some island societies, echinoderms such as sea cucumbers (*Holothuroidea*) are highly valued not only as tonic foods but also as medicinal preparations. Traditional healers in the Maluku and Papua regions prepare sea cucumber extracts for postnatal care, energy restoration, and wound healing. These preparations are considered part of maternal health care regimens, often reserved for postpartum women or the elderly. These uses are supported by modern pharmacological studies that confirm the presence of bioactive triterpene glycosides and fatty acids (Hanifaturahmah et al. 2024).

The cultural use of coral reef biota often intersects with spiritual beliefs and symbolic associations. For instance, certain soft corals or marine sponges may be considered sacred or taboo, their collection permitted only under specific ritual conditions. These ritual constraints reflect a form of traditional resource management, ensuring that harvesting does not exceed ecological thresholds. This intertwining of ecological knowledge and cosmology underscores the importance of respecting cultural context in ethnopharmacological research.

While many of these traditional practices remain undocumented in formal literature, they offer valuable leads for modern pharmacology and highlight the need for biocultural conservation of reef ecosystems and indigenous knowledge systems. Systematic documentation, participatory validation, and equitable benefit-sharing are essential steps to safeguard and ethically utilize this culturally embedded medicinal knowledge.

Documented ethnomedicinal species and applications

Although scientific studies on the traditional medicinal uses of coral reef organisms are relatively sparse compared to terrestrial plants, several marine species have been documented for their ethnomedicinal relevance. These scattered but significant records provide crucial entry points for marine bioprospecting, particularly when linked to contemporary pharmacological assays. Documenting such uses also supports efforts to protect biocultural heritage and prioritize research on species with dual ecological and therapeutic roles.

Sea cucumbers (*Holothuroidea*) are among the most widely used reef-associated organisms in ethnomedicine, particularly in East and Southeast Asia. In traditional Chinese medicine, species such as *Stichopus japonicus* and *Holothuria scabra* are consumed for their purported ability to improve stamina, wound healing, and kidney function (Cutolo et al. 2024; Hanifaturahmah et al. 2024). Similar uses are reported among coastal Indonesian communities, where *teripang* extracts are applied topically to treat burns and muscle pain. These practices are usually administered post-injury or post-surgery, reflecting empirical knowledge of their regenerative properties. Laboratory findings have confirmed the presence of triterpene glycosides and omega-3 fatty acids with anti-inflammatory and immunomodulatory activities, providing a biochemical basis for these traditional uses.

Soft corals from the genera *Sarcophyton* and *Sinularia* have been occasionally referenced in ethnomedicinal surveys, particularly for their use in topical ointments and poultices. While direct human applications are rare due to potential toxicity, some traditional healers—particularly in ritual contexts—prepare low-concentration infusions for treating skin lesions and joint pain. Their chemical richness—including diterpenoids, cembranoids, and prostaglandin-like compounds makes these taxa promising leads for modern drug development, especially in the fields of inflammation and pain modulation (Fristiohady et al. 2019).

Macroalgae, especially brown algae like *Sargassum polycystum*, are more broadly used and better documented in both traditional and modern contexts. Decoctions from dried *Sargassum* are used to treat goiter, menstrual irregularities, and skin conditions in coastal herbal medicine practices in Java and Sulawesi (Darfiah et al. 2021; Husain et al. 2024; Lee et al. 2024). These uses reflect a long-standing empirical tradition of balancing internal heat and detoxification in humoral-based medical systems. Scientific validation has identified fucoidans and sulphated polysaccharides in *Sargassum* with antioxidant, antiviral, and antitumor properties, reinforcing its integration into both functional foods and pharmaceutical research.

Other reef-related organisms, such as sponges (*Haliclona* spp.) and tunicates (*Didemnum* spp.), are rarely mentioned in ethnomedical texts but have shown cytotoxic and antimicrobial activity in pharmacological assays (Cooper et al. 2014). In coastal regions of Papua and select Pacific Island communities, decoctions or washes from sponge tissues are still used to treat skin infections, with preparation methods emphasizing low-dose extraction and topical administration. While tunicates are less commonly recognized in traditional medicine, emerging interest in their bioactivity suggests untapped potential for ethnopharmacological exploration.

The limited but compelling documentation of these species highlights the importance of interdisciplinary methods—combining ethnographic, ecological, and biochemical approaches—to fully capture their medicinal significance. In summary, although the formal literature on coral reef organisms in traditional medicine remains relatively sparse, existing examples suggest a continuity of use that spans cultural, nutritional, and therapeutic domains. These species not only reflect deep ecological knowledge among coastal communities but also provide a starting point for interdisciplinary research that connects ethnopharmacology

with marine biotechnology, drug discovery, and biocultural conservation. Table 3 presents selected examples of coral reef organisms traditionally used in medicine across Southeast Asia, linking local practices with pharmacologically relevant compounds.

Continuity and decline of traditional practices

The transmission of traditional knowledge related to coral reef-based medicine is increasingly threatened by socio-economic change, environmental degradation, and generational discontinuity. In many coastal regions, younger generations are less familiar with the medicinal uses of marine organisms, often viewing such knowledge as outdated or irrelevant in the face of modern healthcare systems (Cutolo et al. 2024). This cultural shift, driven in part by formal education and media exposure, contributes to a loss of confidence in ancestral practices. The erosion of oral traditions poses a critical risk not only to cultural heritage but also to the biocultural diversity that underpins long-term marine pharmacological potential.

One of the primary factors driving this decline is the progressive loss of access to intact and biodiverse coral reef ecosystems. Climate change, destructive fishing practices, pollution, and coastal development have drastically altered reef environments, making many traditionally used species scarce or locally extinct. When resource availability declines, so too does the opportunity for knowledge transfer through observation, collection, and practice. This ecological disconnection disrupts the sensory and experiential learning systems that are foundational to traditional medicine.

In parallel, the increasing dependence on pharmaceutical products and clinical treatment has reduced the perceived value of traditional therapies. While this shift has improved health outcomes in some regions, it also marginalizes ancestral knowledge systems that once provided holistic, community-adapted, and environmentally embedded healthcare solutions. This is particularly problematic in remote island settings where formal healthcare infrastructure remains limited and traditional medicine could still play a complementary or even primary role in public health resilience.

However, there are notable exceptions where traditional marine medicine remains vibrant. In some Pacific Island nations, coral-derived remedies continue to be used alongside modern treatments, often within culturally regulated frameworks. Community-led conservation areas and marine customary tenure systems have also helped preserve both the biological resources and the associated knowledge (Fristiohady et al. 2019). These co-management models demonstrate the feasibility of integrating ecological stewardship with cultural continuity. When cultural institutions and ecological governance mechanisms support traditional practices, they can persist and even be revitalized.

Efforts to document, validate, and revitalize traditional uses of coral reef organisms must therefore be positioned as part of broader, transdisciplinary strategies in marine conservation, ethnopharmacology, and education. By fostering respect for indigenous knowledge and encouraging intergenerational learning, stakeholders can ensure that traditional ethnopharmacology remains a living, evolving part of coastal community identity and resilience. Such approaches are not merely acts of preservation, but investments in future innovation rooted in cultural and ecological integrity.

Integration into contemporary and complementary medicine

The integration of traditional marine-derived remedies into Contemporary and Complementary Medicine (CCM) frameworks is gaining increasing interest among researchers, clinicians, and policy-makers. Many coral reef organisms used in traditional medicine possess bioactive compounds that align with modern pharmacological targets, providing a natural bridge between indigenous knowledge and biomedical innovation (Cooper et al. 2014; Karthikeyan et al. 2022). This convergence reflects a growing recognition that ancestral health systems can contribute meaningfully to diversified, pluralistic healthcare models. Recognizing and respecting this overlap offers both scientific and ethical opportunities to diversify global health resources.

Table 3. Documented ethnomedicinal uses of coral reef organisms in Southeast Asia

Organism	Traditional application	Preparation/form	Region/community	Probable active compound	References
Sarcophyton spp.	Wound treatment, skin rashes	Raw tissue or oil mixture	Maluku, East Nusa Tenggara	Cembranoids, diterpenes	Fristiohady et al. 2019
Sargassum polycystum	Goiter, inflammation, fever	Decoction (dried)	Java, Sulawesi	Fucoidans, sulphated polysaccharides	Darfiah et al. 2021; Husain et al. 2024; Lee et al. 2024
Gracilaria spp.	Blood tonic, menstrual remedy	Boiled or decocted	Northern coastal Java	Sulfated polysaccharides	Nurazizah et al. 2024
Sea cucumber (*Teripang*)	Postpartum care, wound healing	Alcoholic extract, soup	Maluku, Papua	Triterpene glycosides	Hanifaturahmah et al. 2024
Haliclona spp. (sponge)	Skin infections	Boiled and washed	Papua, coastal Kalimantan	Manzamine A, alkaloids	Cooper et al. 2014
Padina australis	Anti-fatigue, diabetes remedy	Tea-like decoction	Eastern Sulawesi	Phlorotannins, flavonoids	Darfiah et al. 2021
Mollusks (mixed species)	Wound drying agent	Crushed shell powder	Central Sulawesi, Java	Calcium salts, trace bioactives	Marwoto et al. 2020; Ngandjui et al. 2024
Pseudoalteromonas (bacteria)	Antiseptic, skin wash	Fermented extract (local)	Unspecified (oral tradition)	Bromoalterochromides	Karthikeyan et al. 2022

One approach to integration involves the rigorous phytochemical characterization and pharmacological validation of traditional remedies. For instance, the traditional use of *Sargassum* decoctions to treat goiter and inflammation has led to the isolation of fucoidans and sulphated polysaccharides with confirmed anti-inflammatory and antithyroid activity (Saraswati et al. 2019; Lomartire and Gonçalves 2022). This discovery not only validates the traditional use of *Sargassum* but also opens up a world of possibilities for the integration of marine compounds into modern pharmacology. Similarly, compounds from sea cucumbers, such as triterpene glycosides, have been developed into commercial health supplements in parts of Asia and the Pacific, demonstrating the economic feasibility of translating traditional marine uses into modern health products.

Incorporating reef-derived natural products into CCM systems requires strict adherence to scientific standards of safety, efficacy, and dosage consistency. Many marine compounds possess narrow therapeutic windows or may interact with conventional drugs, underscoring the need for rigorous pharmacokinetic and toxicological studies. This includes in vivo efficacy trials, metabolic pathway elucidation, and formulation development to improve bioavailability. Nonetheless, when such barriers are addressed, coral-derived agents have potential in areas such as wound healing, cancer support therapy, neurodegeneration, and immune modulation, providing reassurance and confidence in the safety and efficacy of these compounds.

Ethnopharmacological knowledge also contributes to drug discovery by guiding species and compound selection, reducing the need for random screening. For example, observations of traditional wound treatments using soft coral extracts can lead researchers to prioritize cembranoid-rich species for anti-inflammatory assays. Such biocultural targeting not only streamlines research processes but also fosters equitable acknowledgment of local knowledge holders. This targeted approach not only improves research efficiency but also acknowledges and appreciates the intellectual contributions of traditional healers, making them an integral part of the drug discovery process.

Despite these opportunities, integration remains constrained by regulatory, cultural, and logistical barriers. Intellectual property rights and benefit-sharing frameworks are often inadequate or poorly implemented, discouraging communities from sharing knowledge. Moreover, skepticism from both biomedical and traditional sectors can impede mutual understanding. The lack of policy harmonization and scientific literacy within local governance further complicates implementation at the grassroots level. Bridging these divides requires interdisciplinary dialogue, policy reform, and community engagement that places traditional knowledge on equal epistemological footing with modern science.

Several countries have begun to institutionalize marine-based traditional knowledge through herbal pharmacopeias, CCM clinics, and co-designed research protocols. These models offer valuable insights for Indonesia and other coral-rich nations seeking to develop culturally grounded, sustainable health strategies. They also exemplify how respectful integration can be achieved without undermining cultural autonomy. When done responsibly, the integration of coral reef ethnomedicine into modern practice can enrich therapeutic options while strengthening the cultural and ecological foundations of community health.

CHALLENGES AND OPPORTUNITIES IN CORAL-BASED DRUG DISCOVERY

Scientific and technical limitations

Despite the immense pharmacological potential of coral reef-derived compounds, the translation of these natural products into approved therapeutic agents remains limited. Several scientific and technical barriers impede the advancement of coral-based drug discovery from initial bioactivity screening to preclinical and clinical development (Cooper et al. 2014; Karthikeyan et al. 2022). These challenges involve issues of compound supply, structural complexity, reproducibility, and incomplete pharmacological characterization.

One major limitation is the difficulty in obtaining sufficient quantities of bioactive compounds for detailed pharmacological testing. Many coral reef organisms produce secondary metabolites in minute concentrations, often as a defense mechanism under specific environmental conditions. Harvesting large volumes of biomass to isolate these compounds is ecologically unsustainable and technically impractical. Moreover, seasonal variation, habitat-specific stressors, and symbiotic interactions influence the yield and consistency of these metabolites, making reproducibility a significant hurdle. For instance, the diterpenoids found in soft corals such as *Sarcophyton glaucum* are often present in nanomolar concentrations, requiring extensive biomass to yield usable quantities for preclinical trials.

The structural complexity of coral reef-derived compounds also presents obstacles in chemical synthesis and modification. Many compounds from coral reef organisms feature unique scaffolds, multiple stereocenters, and halogenated groups that challenge conventional synthetic chemistry. Although advances in total synthesis and semi-synthesis have enabled production of some compounds in the laboratory, the processes are often low-yielding, expensive, and difficult to scale (Mayer et al. 2013). Compounds like palau'amine and pseudopterosin, while pharmacologically potent, have proven extremely challenging to synthesize due to their polycyclic structures and unstable intermediates. These limitations hinder the development of analogs or derivatives with improved pharmacokinetic profiles.

The lack of standardized bioassay protocols also complicates the evaluation of coral-derived compounds. Bioactivity data are often generated using different cell lines, assay conditions, or extract preparations, leading to inconsistent or non-comparable results across studies. This inconsistency limits the ability to prioritize compounds for further development and impedes meta-analysis or evidence synthesis. Furthermore, the mechanisms of action for many coral reef-derived compounds remain poorly understood, which poses risks for off-target effects or toxicity in

clinical applications. For example, several cembranoids exhibit anti-inflammatory properties in vitro, yet their interaction with human signaling pathways remains unclear, limiting their translational potential.

Another major limitation is the absence of robust in vivo validation. While many compounds exhibit promising effects in vitro, relatively few have been tested in animal models, and even fewer have entered clinical trials. This bottleneck reflects both ethical and logistical challenges and the lack of funding for long-term marine pharmacology programs. Without adequate in vivo data, the therapeutic relevance and safety of these compounds remain speculative. Coral reef-derived compounds like eleutherobin, despite strong in vitro anticancer activity, have stalled in development due to lack of in vivo efficacy and toxicity profiling.

In addition, intellectual property issues and bioprospecting regulations can create legal uncertainties in accessing and developing marine genetic resources. The implementation of the Nagoya Protocol has improved benefit-sharing mechanisms, but also introduced administrative complexities that can deter investment in coral-derived drug development. Unclear ownership of marine resources in biodiversity hotspots such as the Coral Triangle has led to delays in research permitting, complicating timelines for compound validation and technology transfer.

Conservation, sustainability, and ethical considerations

The discovery and utilization of coral reef-derived bioactive compounds must be framed within a broader context of environmental ethics and sustainability. Coral reefs are among the most biodiverse yet fragile ecosystems on Earth, and many of the organisms targeted for bioprospecting—such as soft corals, sponges, and macroalgae—play vital ecological roles in maintaining reef structure and function (Putnam et al. 2017; Cutolo et al. 2024). Overexploitation of these organisms for pharmaceutical or commercial purposes may exacerbate reef degradation and undermine long-term research potential. This is particularly critical in regions already experiencing coral bleaching, pollution, and invasive species, where any additional extraction pressure may trigger cascading ecological impacts.

One of the major concerns in coral-based bioprospecting is the ecological impact of biomass collection. Many bioactive compounds are present in low concentrations, necessitating the harvest of large quantities of organisms to obtain sufficient material for study. Without regulated harvesting protocols, this can lead to the local extinction of slow-growing or habitat-specific species. Moreover, physical damage to reef substrates during collection can reduce coral cover, alter species interactions, and compromise reef resilience. Such practices not only jeopardize biodiversity but also reduce the availability of medicinal resources for future generations.

In response, researchers have emphasized the need for non-destructive sampling techniques and alternative supply strategies. These include aquaculture of target species, microbial fermentation of coral-associated symbionts, and synthetic biology approaches that transfer biosynthetic pathways into model organisms (Karthikeyan et al. 2022). Metabolite extraction from cultured coral fragments or sponge explants, for example, provides a renewable source of compounds without depleting wild populations. Such innovations aim to decouple compound access from ecological damage, making marine drug discovery more sustainable and scalable.

Equally important are ethical and legal considerations surrounding access and benefit-sharing. Many coral reef regions are located in the territorial waters of developing countries, where traditional knowledge and local biodiversity are tightly interwoven. The Convention on Biological Diversity (CBD) and its supplementary Nagoya Protocol mandate fair and equitable sharing of benefits arising from the utilization of genetic resources. However, enforcement and compliance mechanisms vary across jurisdictions, and many communities remain undercompensated for their contributions to marine bioprospecting (Putnam et al. 2017). In some cases, lack of legal clarity regarding traditional knowledge ownership has led to biopiracy and mistrust, impeding collaborative research.

Community engagement and co-design of research projects offer promising pathways for ethical marine bioprospecting. Incorporating local knowledge, involving indigenous stakeholders, and ensuring transparent agreements are essential steps toward decolonizing research practices and fostering inclusive conservation. Ethical frameworks that integrate social equity with ecological stewardship are increasingly recognized as best practices in coral reef-derived compounds development. These frameworks should include long-term benefit-sharing schemes, intellectual property protection for traditional healers, and capacity-building initiatives within local research institutions.

Conservation of coral reef biodiversity is not only a moral imperative but also a strategic investment in pharmaceutical innovation. The vast majority of coral reef species remain chemically uncharacterized, and their extinction would represent the irreversible loss of genetic and biochemical resources. Marine Protected Areas (MPAs), sustainable fisheries, and climate adaptation strategies are thus indispensable in maintaining the natural laboratories from which new medicines may emerge. Linking marine conservation goals with drug discovery initiatives can promote synergistic funding opportunities and shared stewardship among scientific and local communities.

In summary, coral-based drug discovery must operate at the intersection of science, ethics, and environmental responsibility. Sustainable collection, fair benefit-sharing, and active reef conservation are prerequisites for ensuring that future generations can continue to explore and benefit from coral ecosystems' medicinal richness. By embedding ecological limits and cultural respect into research protocols, marine pharmacology can evolve into a model of sustainable innovation.

Knowledge gaps and underexplored taxa

Despite decades of marine pharmacological research, significant knowledge gaps persist in the study of coral reef-derived bioactive compounds. Much of the existing literature is focused on a relatively small subset of soft corals, sponges, and macroalgae, while the majority of

coral reef-associated organisms remain chemically and pharmacologically unexplored (Mayer et al. 2013; Fristiohady et al. 2019). This taxonomic bias not only limits the discovery of novel bioactive scaffolds but also constrains our understanding of chemical diversity within reef ecosystems.

Among the underexplored taxa are a wide array of sessile invertebrates, symbiotic microorganisms, and cryptic coral species. For example, tunicates, bryozoans, and foraminifera associated with reef systems are known to produce unique secondary metabolites in other ecosystems but have received minimal attention in tropical coral contexts (Karthikeyan et al. 2022). Many of these organisms possess specialized ecological roles and metabolic pathways that may give rise to rare or structurally novel compounds. These organisms may harbor biosynthetic gene clusters capable of producing novel bioactive scaffolds, yet few have been subjected to modern genomic or metabolomic analyses.

Microbial symbionts—particularly bacteria and fungi associated with coral mucus and skeletons—represent another promising but understudied group. These microorganisms often produce bioactive compounds in situ, possibly contributing to the host's chemical defense mechanisms. Some marine-derived antibiotics and anticancer agents originally attributed to macroorganisms have later been traced to associated microbes (Cooper et al. 2014). Recent advancements in metagenomics, metatranscriptomics, and single-cell sequencing are making it increasingly feasible to decode these hidden biosynthetic potentials. The integration of multi-omics approaches could reveal microbial contributions to coral resilience and chemical defense, offering new leads for drug development.

In terms of pharmacological screening, the majority of coral-derived compounds have been tested for antibacterial or cytotoxic effects, with far fewer studies investigating neuroprotective, metabolic, or immunomodulatory properties. This creates a mismatch between therapeutic demand—especially for chronic, non-communicable diseases—and the current direction of coral pharmacology. Emerging global health challenges such as antibiotic resistance, neurodegeneration, and metabolic disorders demand a broader repertoire of pharmacological targets and bioassay systems. Expanding the scope of bioassays and disease models is necessary to uncover the full therapeutic relevance of marine compounds.

There is also a lack of longitudinal and ecological studies that link compound production to environmental conditions, symbiotic relationships, or stress responses. Understanding these ecological drivers could improve the predictability and yield of bioactive compound production. Such insights are particularly relevant in the face of climate change, as reef organisms adapt their metabolic outputs in response to environmental stressors. Monitoring metabolite plasticity over time and space can help identify optimal conditions for compound harvesting or synthesis.

Additionally, many bioactive leads remain chemically uncharacterized or poorly annotated due to limitations in dereplication, compound isolation, or spectral library access. High-throughput dereplication workflows, supported by machine learning and cloud-based compound libraries, are essential to avoid redundant rediscovery and accelerate innovation. Investment in mass spectrometry, NMR-based structural elucidation, and integrated compound databases is essential to accelerate identification and improve data sharing across disciplines.

In conclusion, the field of coral reef drug discovery stands to benefit greatly from expanding its taxonomic, ecological, and pharmacological horizons. By prioritizing underexplored taxa and addressing persistent knowledge gaps, researchers can unlock new dimensions of coral reef biodiversity with transformative implications for medicine and conservation. Targeted exploration combined with interdisciplinary technologies offers a pathway toward more inclusive, efficient, and impactful marine bioprospecting.

Strategic opportunities and emerging technologies

While significant, the challenges of coral-based drug discovery are counterbalanced by a rapidly evolving landscape of technological innovations and strategic approaches that can accelerate and diversify the search for coral reef-derived compounds. Interdisciplinary collaborations, digital tools, and advanced biotechnologies are opening new frontiers in coral pharmacology (Cooper et al. 2014; Karthikeyan et al. 2022). These developments represent a paradigm shift in coral reef-derived compounds research, offering innovative solutions to long-standing limitations such as low compound yield, structural complexity, and ecological constraints.

One promising development is the application of genome mining and synthetic biology to uncover and replicate biosynthetic pathways from coral reef organisms and their symbionts. Many of the compounds of interest are encoded by Biosynthetic Gene Clusters (BGCs) in microbial or invertebrate genomes. By identifying these genes and inserting them into fast-growing host organisms (e.g., *E. coli* or *Streptomyces*), it becomes possible to produce target compounds at scale without harvesting the source organisms (Mayer et al. 2013). This biotechnological approach not only enables sustainable compound production but also facilitates structural modification and pathway engineering for improved pharmacokinetics and therapeutic selectivity.

Metabolomics and cheminformatics tools now allow for high-throughput screening and dereplication of complex coral extracts. Mass spectrometry-based molecular networking, for example, helps to identify novel scaffolds and prioritize bioactive candidates rapidly. These platforms are increasingly integrated with AI-driven predictive models that can simulate bioactivity, toxicity, and target binding, reducing the need for early-stage in vivo assays. Such integration of computational chemistry and machine learning has greatly enhanced the speed, precision, and reproducibility of compound discovery pipelines.

Aquaculture and marine biotechnology also present sustainable production pathways. Soft corals, sponges, and algae can be cultured in controlled environments such as floating ocean farms or land-based tanks. Cultivation not only ensures renewable access to bioresources but also allows manipulation of environmental factors to enhance metabolite production (Leal et al. 2013; Chang and Nichols

2024). Emerging techniques such as bioreactor cultivation, cryopreservation of germplasm, and stress-induced elicitation are further expanding the scalability and consistency of bioactive yields. Moreover, co-cultivation with symbiotic microbes may recreate natural chemical interactions critical to compound biosynthesis.

Marine drug discovery is also benefiting from advances in nanotechnology and drug delivery systems. Encapsulating coral-derived compounds in nanoparticles, liposomes, or emulsions can enhance their stability, solubility, and target specificity, especially for compounds with low bioavailability or high reactivity. Recent studies have demonstrated the efficacy of these delivery platforms in improving the pharmacodynamics of marine compounds, particularly in cancer therapeutics and neurodegenerative disorders. This is particularly relevant for anticancer and neuroprotective agents derived from marine steroids, terpenes, and flavonoids.

Policy and innovation frameworks are beginning to support marine biodiscovery more explicitly. Initiatives such as the UN Decade of Ocean Science (2021-2030) and national marine bioprospecting strategies aim to promote the sustainable use of marine genetic resources while ensuring benefit-sharing with local communities. Regional collaborations, digital bioresource platforms, and blue economy incentives are also contributing to a more supportive ecosystem for marine drug innovation. These global movements align marine research with ethical, environmental, and economic imperatives.

In summary, the future of coral reef drug discovery depends not only on biological curiosity but on our ability to integrate technology, ethics, and ecology strategically. By embracing emerging tools and cross-sector collaboration, we can harness coral biodiversity in ways that are both scientifically productive and socially responsible. The convergence of biotechnological advances, ethical bioprospecting practices, and marine policy innovation offers a promising pathway toward a more inclusive and sustainable era of marine pharmacology.

Toward a sustainable research framework

As coral reef-derived compounds research advances, there is a growing need to establish sustainable frameworks that integrate drug discovery, biodiversity conservation, and socio-cultural equity. Coral reef-based pharmacological exploration, in particular, requires a deliberate shift from extractive practices toward collaborative, regenerative, and ethically grounded research models (Putnam et al. 2017; Fristiohady et al. 2019). Such a paradigm shift ensures that marine drug discovery progresses in tandem with ecological stewardship, social justice, and long-term scientific relevance.

First and foremost, sustainability in coral-based research demands ecological responsibility. Field sampling protocols should prioritize non-destructive or minimally impactful techniques, such as fragment collection, remote sensing-guided harvesting, or reliance on aquaculture specimens. The adoption of ecological monitoring and habitat-sensitive harvesting zones should become a standard practice. Environmental Impact Assessments (EIAs) must be standardized and integrated into all stages of marine bioprospecting, from exploration to compound extraction. Marine Protected Areas (MPAs) and no-take zones should be recognized not as barriers but as ecological reservoirs and biobanks that safeguard the evolutionary potential of reef organisms and the continuity of marine chemical diversity.

Second, the framework must embed equitable benefit-sharing and community participation. Many biodiverse coral reef regions are located within indigenous or traditional territories. The principles of Free, Prior, and Informed Consent (FPIC), as outlined in the Nagoya Protocol, should guide all access to genetic resources and associated knowledge. Co-authorship with local experts, revenue-sharing agreements, and reinvestment in local conservation programs are essential components of ethical bioprospecting (Cutolo et al. 2024). This approach not only acknowledges local rights and expertise but also strengthens social legitimacy and long-term collaboration.

Integration between traditional knowledge systems and modern pharmacology offers a strategic advantage. Ethnomedical insights can guide the prioritization of species and compounds, improving discovery efficiency and cultural relevance. However, mechanisms must be in place to protect intellectual property rights and ensure that traditional healers and knowledge holders are recognized as legitimate contributors. Models of reciprocal knowledge exchange and community-curated ethnobotanical registries can enhance both scientific rigor and cultural preservation. Community-based research models that co-develop hypotheses, methods, and interpretations can generate more holistic and actionable knowledge.

Institutionally, sustainable marine drug discovery calls for long-term investment and capacity building. This includes infrastructure for compound isolation, genome sequencing, bioassay screening, and data sharing in coastal regions where coral diversity is highest. Academic partnerships between institutions in the Global North and South must aim for equitable collaboration, avoiding extractive or asymmetrical dynamics. Investment in local laboratories, marine stations, and open-access training programs will ensure that capacity remains embedded in biodiversity-rich regions. Education and training of local researchers, particularly in bioinformatics, marine pharmacology, and policy, will be vital for sustained impact.

Lastly, a sustainable research framework should promote transparency, open data, and knowledge circulation. Databases that catalog coral reef-derived compounds, their sources, activities, and associated metadata should be made interoperable and accessible to diverse stakeholders. These resources can also aid in the development of early-warning systems to monitor biodiversity loss and chemical diversity decline due to climate change and reef degradation. Global repositories such as MarinLit or GNPS (Global Natural Products Social Molecular Networking) should be expanded to include locally generated data and ensure representation of underexplored regions.

In conclusion, coral-based bioprospecting must evolve beyond opportunistic collection toward a comprehensive, participatory, and conservation-oriented research ecosystem. Such a framework not only secures the ecological foundation for discovery but also elevates the ethical and scientific integrity of marine pharmacology. Moving forward,

sustainability must be positioned as a core principle rather than a secondary consideration in marine biomedical innovation.

Collectively, the challenges and opportunities discussed here underscore the urgency of rethinking coral-based drug discovery through an integrated, ethical, and future-oriented lens. The next chapter further explores how these insights can shape strategic policy frameworks and translational applications.

CONCLUSION AND FUTURE PERSPECTIVES

Coral reef ecosystems harbor a vast reservoir of bioactive compounds with remarkable structural diversity and pharmacological potential. Soft corals, sponges, macroalgae, and their associated symbionts have yielded metabolites exhibiting a wide spectrum of biological activities, including antibacterial, anti-inflammatory, cytotoxic, neuroprotective, antioxidant, and immunomodulatory effects. These findings highlight the strategic role of coral reefs in the advancement of drug discovery. However, the translation of these natural products into clinically approved therapies remains constrained by persistent challenges such as limited compound yield, structural complexity, and ecological sensitivity. Moreover, the chemical and pharmacological profiles of many reef organisms remain uncharacterized, underscoring the urgency to expand both taxonomic exploration and therapeutic screening.

To unlock the full potential of coral-based pharmacology, future research must be guided by a convergence of technological innovation, ecological responsibility, and ethical engagement. Emerging tools such as genome mining, metabolomics, synthetic biology, and AI-driven bioinformatics offer promising solutions for overcoming conventional barriers in marine bioprospecting. Equally essential is the integration of traditional ecological knowledge, equitable benefit-sharing, and community-based conservation strategies. A sustainable research framework that safeguards biodiversity while fostering interdisciplinary collaboration and local capacity building will be critical in transforming coral reefs into enduring sources of biomedical innovation. By embracing this holistic paradigm, coral reef ecosystems can be valued not only for their pharmacological promise but also for their ecological and cultural significance in a rapidly changing world.

REFERENCES

Anastyuk SD, Shevchenko NM, Menshova RVU, Silchenko AS, Zadorozhny PA, Dmitrenok PS, Ermakova SP. 2017. Structural features and anticancer activity in vitro of fucoidan derivatives from brown alga *Saccharina cichorioides*. Carbohydr Polym 157: 1503-1510. DOI: 10.1016/j.carbpol.2016.11.031.

Asaad I, Lundquist CJ, Erdmann MV, Costello MJ. 2020. The coral triangle: The most species rich marine region on earth. In: Goldstein MI, DellaSala DA (eds). Encyclopedia of the World's Biomes. Elsevier Inc., Amsterdam, Netherlands. DOI: 10.1016/B978-0-12-409548-9.11801-9.

Avila-Romero M, García-Bores AM, Garduño-Solorzano G, Avila-Acevedo JG, Serrano-Parrales R, Orozco-Martínez J, Meraz-Martínez S, Peñalosa-Castro I, Estrella-Parra EA, Valencia-Quiroz I, Hernandez-Delgado T. 2022. Antimicrobial activity of some macroalgae of the Veracruzano Reef System (SAV), Mexico. Saudi J Biol Sci 30 (1): 103496. DOI: 10.1016/j.sjbs.2022.103496.

Bell JB, Micaroni V, Strano F. 2022. Regime shifts on tropical coral reef ecosystems: future trajectories to animal-dominated states in response to anthropogenic stressors. Emerg Topics Life Sci 6 (1): 95-106. DOI: 10.1042/ETLS20210231.

Blunt JW, Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. 2018. Marine natural products. Nat Prod Rep 35 (1): 8-53. DOI: 10.1039/c7np00052a.

Chang KJL, Nichols PD. 2024. Marine biotechnology for sustainability of ecologically significant resources. Sustainability 16 (23): 10664. DOI: 10.3390/su162310664.

Changyun W, Haiyan L, Changlun S, Yanan W, Liang L, Huashi G. 2008. Acta Ecol Sin 28: 2320-2328. DOI: 10.1016/S1872-2032(08)60048-7.

Chen C-H, Chen N-F, Feng C-W, Cheng S-Y, Hung H-C, Tsui K-H, Hsu C-H, Sung P-J, Chen W-F, Wen Z-H. 2016. A coral-derived compound improves functional recovery after spinal cord injury through its antiapoptotic and anti-inflammatory effects. Mar Drugs 14 (9): 160. DOI: 10.3390/md14090160.

Cooper EL, Hirabayashi K, Strychar KB, Sammarco PW. 2014. Corals and their potential applications to integrative medicine. Evid Based Complement Alternat Med 2014: 184959. DOI: 10.1155/2014/184959.

Cutolo EA, Campitiello R, Caferri R, Pagliuca VF, Li J, Agathos SN, Cutolo M. 2024. Immunomodulatory compounds from the sea: From the origins to a modern marine Pharmacopoeia. Mar Drugs 22 (7): 304. DOI: 10.3390/md22070304.

Darfiah, Kasmiati, Latama G. 2021. Antibacterial activity and identification of active compounds of seaweed extract *Sargassum* sp., *Halimeda opuntia* and *Halymenia* sp. from Lae-Lae Island of South Sulawesi. Intl J Environ Agric Biotechnol 6: 187-195. DOI: 10.22161/ijeab.66.23.

dos Santos GS, de Souza TL, Teixeira TR, Brandão JPC, Santana KA, Barreto LHS, de Souza Cunha S, dos Santos DCMB, Caffrey CR, Pereira NS, de Freitas Santos Júnior A. 2023. Seaweeds and corals from the Brazilian coast: Review on biotechnological potential and environmental aspects. Molecules 28 (11): 4285. DOI: 10.3390/molecules28114285.

Ermolenko EV, Imbs AB, Gloriozova TA, Poroikov VV, Sikorskaya TV, Dembitsky VM. 2020. Chemical diversity of soft coral steroids and their pharmacological activities. Mar Drugs 18 (12): 613. DOI: 10.3390/md18120613.

Fristiohady A, Wahyuni W, Malik F, Leorita M, Yusuf MI, Febriansyah H, Sahidin S. 2019. Efek imunomodulator ekstrak etanol spons *Xestospongia* sp. terhadap aktivitas fagositosis makrofag pada mencit jantan galur Balb/c. J Mandala Pharmacon Indonesia 5 (1): 15-30. DOI: 10.35311/jmpi.v5i01.38. [Indonesian]

Fudjaja I, Viantika NM, Rani C, Nurdin N, Priosambodo D, Tenriawaru AN. 2020. Anthropogenic activity and the destruction of coral reefs in the waters of small islands. IOP Conf Ser: Earth Environ Sci 575: 012057. DOI: 10.1088/1755-1315/575/1/012057.

Gan SY, Wong LZ, Wong JW, Tan EL. 2019. Fucosterol exerts protection against amyloid β-induced neurotoxicity, reduces intracellular levels of amyloid β and enhances the mRNA expression of neuroglobin in amyloid β-induced SH-SY5Y cells. Intl J Biol Macromol 121: 207-213. DOI: 10.1016/j.ijbiomac.2018.10.021.

Hadi TA, Abrar M, Giyanto, Prayudha B, Johan O, Budiyanto A, Dzumalek AR, Alifatri LO, Sulha S, Suharsono. 2020. The Status of Indonesian Coral Reefs 2019. Research Center for Oceanography, Puslit Oseanografi-LIPI, Jakarta. [Indonesian]

Hanafy AM, Khattab RA, Al-Reedy RM. 2022. Phylogenetic affiliation of bioactive metabolites producing bacterial symbionts associated with soft corals from the Red Sea. Egypt J Aquat Res 48 (4): 359-366. DOI: 10.1016/j.ejar.2022.05.004.

Hanifaturahmah F, Dewanti-Hariyadi R, Hasanah U, Nurilmala M. 2024. Karakteristik kimia dan aktivitas antioksidan teripang (*Holothuria* sp.) segar dan olahan secara tradisional di Papua Barat. Jurnal Pengolahan Hasil Perikanan Indonesia 27 (4): 309-318. DOI: 10.17844/jphpi.v27i4.51323. [Indonesian]

Husain F, Kundi M, Abdullah A, Lyndon NA, Purnomo A, Fajar, Wahidah BF, Yuniati E. 2024. The utilization of plants in traditional medicine and rituals of Karimunjawa Island community, Central Java, Indonesia. J Mar Isl Cult 13: 113-135. DOI: 10.21463/jmic.2024.13.3.07.

Indriana LF, Marjuky, Hilyana S. 2015. The utilization of seagrass and macroalgae substrate for settlement of sandfish *Holothuria scabra* larvae. Jurnal Akuakultur Indonesia 13 (1): 68-72. DOI: 10.19027/jai.13.68-72. [Indonesian]

Kang HK, Lee HH, Seo CH, Park Y. 2019. Antimicrobial and immunomodulatory properties and applications of marine-derived proteins and peptides. Mar Drugs 17 (6): 350. DOI: 10.3390/md17060350.

Karthikeyan A, Joseph A, Nair BG. 2022. Promising bioactive compounds from the marine environment and their potential effects on various diseases. J Genet Eng Biotechnol 20: 14. DOI: 10.1186/s43141-021-00290-4.

Leal MC, Calado R, Sheridan C, Alimonti A, Osinga R. 2013. Coral aquaculture to support drug discovery. Trends Biotechnol 31 (10): 555-561. DOI: 10.1016/j.tibtech.2013.06.004.

Lee M-K, Jeong HH, Kim M-J, Seo JS, Hwang JY, Jung W-K, Moon KM, Lee I, Lee B. 2024. The beneficial roles of *Sargassum* spp. in skin disorders. J Med Food 27: 359-368. DOI: 10.1089/jmf.2023.K.0160.

Liu L, Heinrich M, Myers S, Dworjanyn SA. 2012. Towards a better understanding of medicinal uses of the brown seaweed *Sargassum* in Traditional Chinese Medicine: a phytochemical and pharmacological review. J Ethnopharmacol 142: 591-619. DOI: 10.1016/j.jep.2012.05.046.

Lomartire S, Gonçalves AMM. 2022. An overview of potential seaweed-derived bioactive compounds for pharmaceutical applications. Mar Drugs 20 (2): 141. DOI: 10.3390/md20020141.

Marwoto RM, Heryanto, Isnaningsih NR, Mujiono N, Alfiah, Prihandini R. 2020. Moluska Jawa (Gastropoda & Bivalvia). IPB Press, Bogor. [Indonesian]

Mayer AMS, Rodríguez AD, Taglialatela-Scafati O, Fusetani N. 2013. Marine pharmacology in 2009-2011: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other Miscellaneous mechanisms of action. Mar Drugs 11 (7): 2510-2573. DOI: 10.3390/md11072510.

Ministry of Maritime Affairs and Fisheries. 2020. Management of Marine Protected Areas in Indonesia: Status and Challenges. Ministry of Maritime Affairs and Fisheries and WWF Indonesia Foundation. Jakarta, Indonesia. [Indonesian]

Munasik, Sabdono A, Assyfa AN, Wijayanti DP, Sugiyanto, Irwani I, Pribadi R. 2020. Coral transplantation on a multilevel substrate of Artificial Patch Reefs: Effect of fixing methods on the growth rate of two *Acropora* species. Biodiversitas 21 (5): 1816-1822. DOI: 10.13057/biodiv/d210507.

Ngandjui YAT, Kereeditse TT, Kamika I, Madikizela LM, Msagati TAM. 2024. Nutraceutical and medicinal importance of marine molluscs. Mar Drugs 22 (5): 201. DOI: 10.3390/md22050201.

Nurazizah S, Rustamsyah A, Perdana F, Sujana D, Kusmiyati M. 2023. Review: Aktivitas farmakologi rumput laut genus *Gracilaria* (Rhodopyceae). Jurnal Farmasi Sains dan Terapan 10 (1): 38-43. DOI: 10.33508/jfst.v10i1.4318. [Indonesian]

Nusaly VR, Wewengkang DS, Rumondor E. 2024. Uji aktivitas antibakteri ekstrak spons *Callyspongia aerizusa* dari perairan Desa Poopoh Kabupaten Minahasa. Pharmacon 13 (1): 409-418. DOI: 10.35799/pha.13.2024.49230. [Indonesian]

Pangestuti R, Arifin Z. 2017. Medicinal and health benefit effects of functional sea cucumbers. J Tradit Complement Med 8 (3): 341-351. DOI: 10.1016/j.jtcme.2017.06.007.

Pirian K, Moein S, Sohrabipour J, Rabiei R, Blomster J. 2017. Antidiabetic and antioxidant activities of brown and red macroalgae from the Persian Gulf. J Appl Phycol 29: 3151-3159. DOI: 10.1007/s10811-017-1152-0.

Putnam HM, Barott KL, Ainsworth TD, Gates RD. 2017. The vulnerability and resilience of reef-building corals. Curr Biol 27 (11): R528-R540. DOI: 10.1016/j.cub.2017.04.047.

Putra A, Nurma N, Rauf A, Yusuf K, Larasati RF, Hawati H, Jaya MM, Suriadin H, Aini S, Nurlaela E. 2022. Identifikasi bentuk pertumbuhan karang keras (hard coral) di Perairan Pulau Jinato Kawasan Taman Nasional Taka Bonerate, Kepulauan Selayar. Fish Wallacea J 3 (1): 1-13. [Indonesian]

Qin L, Yang Y, Mao W. 2023. Anticoagulant property of a sulfated polysaccharide with unique structural characteristics from the green alga *Chaetomorpha aerea*. Mar Drugs 21 (2): 88. DOI: 10.3390/md21020088.

Rahman MA, Oomori T, Wörheide G. 2011. Calcite formation in soft coral sclerites is determined by a single reactive extracellular protein. J Biol Chem 286: 31638-31649. DOI: 10.1074/jbc.M109.070185.

Saraswati, Giriwono PE, Iskandriati D, Tan CP, Andarwulan N. 2019. *Sargassum* seaweed as a source of anti-inflammatory substances and the potential insight of the tropical species: A review. Mar Drugs 17 (10): 590. DOI: 10.3390/md17100590.

Song Y, Cai Z-H, Lao Y-M, Jin H, Ying K-Z, Lin G-H, Zhou J. 2018. Antibiofilm activity substances derived from coral symbiotic bacterial extract inhibit biofouling by the model strain *Pseudomonas aeruginosa* PAO1. Microb Biotechnol 11 (6): 1090-1105. DOI: 10.1111/1751-7915.13312.

Varijakzhan D, Loh J-Y, Yap W-S, Yusoff K, Seboussi R, Lim S-HE, Lai K-S, Chong C-M. 2021. Bioactive compounds from marine sponges: Fundamentals and applications. Mar Drugs 19 (5): 246. DOI: 10.3390/md19050246.

Zhao Y-C, Xue C-H, Zhang T-T, Wang Y-M. 2018. Saponins from sea cucumber and their biological activities. J Agric Food Chem 66 (28): 7222-7237. DOI: 10.1021/acs.jafc.8b01770.